{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:05Z","timestamp":1792788005936,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2023A1515140148"],"award-info":[{"award-number":["2023A1515140148"]}]},{"name":"High-level Talent Research Funding Program of The First Dongguan Affiliated Hospital of Guangdong Medical University","award":["GCC2023004"],"award-info":[{"award-number":["GCC2023004"]}]},{"name":"Special Project for Clinical and Basic Sci&Tech Innovation of Guangdong Medical University","award":["GDMULCJC2024098"],"award-info":[{"award-number":["GDMULCJC2024098"]}],"id":[{"id":"https:\/\/ror.org\/04k5rxe29","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Guangdong Medical University Undergraduate Innovation and Entrepreneurship Education Base Project","award":["JDXM2024070F"],"award-info":[{"award-number":["JDXM2024070F"]}],"id":[{"id":"https:\/\/ror.org\/04k5rxe29","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Guangdong Medical University 2026 High-level Talent Research Start-up Funding","award":["4SG26149G"],"award-info":[{"award-number":["4SG26149G"]}],"id":[{"id":"https:\/\/ror.org\/04k5rxe29","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08765-z","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:17:53Z","timestamp":1787314673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autocrine PD-1-blocking nanobodies enhance the antitumor efficacy of TCR-like CAR-T cells by attenuating t cell exhaustion"],"prefix":"10.1186","volume":"24","author":[{"given":"Wanjun","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songshan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Asad","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0481-9625","authenticated-orcid":false,"given":"Guangxian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"1","key":"8765_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-024-01639-1","volume":"17","author":"H Huang","year":"2024","unstructured":"Huang H, Yu L, Weng H, Zhang W, Wang Z, Wang L, et al. Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress. J Hematol Oncol. 2024;17(1):120.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"8765_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2174\/0115748928277331231218115402","volume":"19","author":"Y Liu","year":"2024","unstructured":"Liu Y, Peng C, Ahad F, Ali Zaidi SA, Muluh TA, Fu Q. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies. Recent Pat Anticancer Drug Discov. 2024;19(5):557\u201372.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"4","key":"8765_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"1","key":"8765_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","volume":"11","author":"J Li","year":"2018","unstructured":"Li J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol. 2018;11(1):22.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"8765_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11427-016-5027-4","volume":"59","author":"B-L Zhang","year":"2016","unstructured":"Zhang B-L, Qin D-Y, Mo Z-M, Li Y, Wei W, Wang Y-S, et al. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Sci China Life Sci. 2016;59(4):340\u20138.","journal-title":"Sci China Life Sci"},{"key":"8765_CR6","doi-asserted-by":"crossref","unstructured":"Nishikawa H, Koyama S. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer. 2021;9(7):e002591.","DOI":"10.1136\/jitc-2021-002591"},{"issue":"3","key":"8765_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ccell.2023.02.009","volume":"41","author":"L van Vlerken-Ysla","year":"2023","unstructured":"van Vlerken-Ysla L, Tyurina YY, Kagan VE, Gabrilovich DI. Functional states of myeloid cells in cancer. Cancer Cell. 2023;41(3):490\u2013504.","journal-title":"Cancer Cell"},{"key":"8765_CR8","doi-asserted-by":"publisher","first-page":"106988","DOI":"10.1016\/j.phrs.2023.106988","volume":"198","author":"M-Y Huang","year":"2023","unstructured":"Huang M-Y, Chen Y-C, Lyu W-Y, He X-Y, Ye Z-H, Huang C-Y, et al. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8\u2009+\u2009T cells via increasing intratumoral CXCL10. Pharmacol Res. 2023;198:106988.","journal-title":"Pharmacol Res"},{"issue":"679","key":"8765_CR9","doi-asserted-by":"publisher","first-page":"eabn5029","DOI":"10.1126\/scitranslmed.abn5029","volume":"15","author":"X Wang","year":"2023","unstructured":"Wang X, Zha H, Wu W, Yuan T, Xie S, Jin Z, et al. CD200\u2009+\u2009cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1\/PD-L1 therapy. Sci Transl Med. 2023;15(679):eabn5029.","journal-title":"Sci Transl Med"},{"issue":"1","key":"8765_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12951-022-01266-3","volume":"20","author":"H Chen","year":"2022","unstructured":"Chen H, Zhang P, Shi Y, Liu C, Zhou Q, Zeng Y, et al. Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy. J Nanobiotechnol. 2022;20(1):61.","journal-title":"J Nanobiotechnol"},{"issue":"10278","key":"8765_CR11","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","volume":"397","author":"F Meric-Bernstam","year":"2020","unstructured":"Meric-Bernstam F, Larkin J, Tabernero J, Bonini C. Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet. 2020;397(10278):1010\u201322.","journal-title":"Lancet"},{"issue":"9","key":"8765_CR12","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","volume":"22","author":"X Zhou","year":"2021","unstructured":"Zhou X, Yao Z, Bai H, Duan J, Wang Z, Wang X, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021;22(9):1265\u201374.","journal-title":"Lancet Oncol"},{"issue":"1","key":"8765_CR13","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.1038\/s41467-020-19498-y","volume":"11","author":"G Lu","year":"2020","unstructured":"Lu G, Nishio N, van den Berg NS, Martin BA, Fakurnejad S, van Keulen S, et al. Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates. Nat Commun. 2020;11(1):5667.","journal-title":"Nat Commun"},{"issue":"1","key":"8765_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-023-01830-x","volume":"22","author":"J Chen","year":"2023","unstructured":"Chen J, Zhu T, Jiang G, Zeng Q, Li Z, Huang X. Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer. Mol Cancer. 2023;22(1):131.","journal-title":"Mol Cancer"},{"key":"8765_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.canlet.2021.09.028","volume":"522","author":"W Shi","year":"2021","unstructured":"Shi W, Yang X, Xie S, Zhong D, Lin X, Ding Z, et al. A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine. Cancer Lett. 2021;522:184\u201397.","journal-title":"Cancer Lett"},{"issue":"22","key":"8765_CR16","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review. JAMA. 2024;332(22):1924\u201335.","journal-title":"JAMA"},{"issue":"4","key":"8765_CR17","doi-asserted-by":"publisher","first-page":"200892","DOI":"10.1016\/j.omton.2024.200892","volume":"32","author":"Z Duan","year":"2024","unstructured":"Duan Z, Li D, Li N, Lin S, Ren H, Hong J, et al. CAR-T cells based on a TCR mimic nanobody targeting HPV16 E6 exhibit antitumor activity against cervical cancer. Mol Ther Oncol. 2024;32(4):200892.","journal-title":"Mol Ther Oncol"},{"issue":"1","key":"8765_CR18","doi-asserted-by":"publisher","first-page":"200948","DOI":"10.1016\/j.omton.2025.200948","volume":"33","author":"Q Lin","year":"2025","unstructured":"Lin Q, Jin S, Wang M. CAR-T cell therapy based on a TCR mimic nanobody targeting an intracellular antigen for solid cancers. Mol Ther Oncol. 2025;33(1):200948.","journal-title":"Mol Ther Oncol"},{"issue":"25","key":"8765_CR19","doi-asserted-by":"publisher","first-page":"7772","DOI":"10.7150\/thno.34941","volume":"9","author":"Q Lecocq","year":"2019","unstructured":"Lecocq Q, De Vlaeminck Y, Hanssens H, D\u2019Huyvetter M, Raes G, Goyvaerts C, et al. Theranostics in immuno-oncology using nanobody derivatives. Theranostics. 2019;9(25):7772\u201391.","journal-title":"Theranostics"},{"issue":"1","key":"8765_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12943-025-02270-5","volume":"24","author":"L Maksymova","year":"2025","unstructured":"Maksymova L, Pilger YA, Nuhn L, Van Ginderachter JA. Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines. Mol Cancer. 2025;24(1):65.","journal-title":"Mol Cancer"},{"issue":"176","key":"8765_CR21","doi-asserted-by":"publisher","first-page":"176ra33","DOI":"10.1126\/scitranslmed.3005661","volume":"5","author":"T Dao","year":"2013","unstructured":"Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med. 2013;5(176):176ra33.","journal-title":"Sci Transl Med"},{"issue":"8","key":"8765_CR22","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/leu.2016.373","volume":"31","author":"S Rafiq","year":"2016","unstructured":"Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, et al. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia. 2016;31(8):1788\u201397.","journal-title":"Leukemia"},{"key":"8765_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.bej.2018.01.010","volume":"132","author":"S Inwood","year":"2018","unstructured":"Inwood S, Xu H, Black MA, Betenbaugh MJ, Feldman S, Shiloach J. Continuous production process of retroviral vector for adoptive T- cell therapy. Biochem Eng J. 2018;132:145\u201351.","journal-title":"Biochem Eng J"},{"key":"8765_CR24","doi-asserted-by":"crossref","unstructured":"Zhang Y, Yang S, Jiang D, Li Y, Ma S, Wang L et al. Screening and identification of an anti-PD-1 nanobody with antitumor activity. Biosci Rep. 2022;43(1):BSR20221546.","DOI":"10.1042\/BSR20221546"},{"key":"8765_CR25","doi-asserted-by":"crossref","unstructured":"Siddiqui S, Liv\u00e1k F. Principles of advanced flow cytometry: a practical guide. Methods Mol Biol. 2023;2580:89\u2013117.","DOI":"10.1007\/978-1-0716-2740-2_5"},{"issue":"6","key":"8765_CR26","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1007\/s10565-023-09821-w","volume":"39","author":"L-L Lu","year":"2023","unstructured":"Lu L-L, Xiao S-X, Lin Z-Y, Bai J-J, Li W, Song Z-Q, et al. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy. Cell Biol Toxicol. 2023;39(6):3101\u201319.","journal-title":"Cell Biol Toxicol"},{"issue":"7","key":"8765_CR27","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood.2021012634","volume":"139","author":"EA Chong","year":"2022","unstructured":"Chong EA, Alanio C, Svoboda J, Nasta SD, Landsburg DJ, Lacey SF, et al. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 2022;139(7):1026\u201338.","journal-title":"Blood"},{"issue":"8","key":"8765_CR28","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu U, Castelli S, June CH. CAR T cell combination therapies to treat cancer. Cancer Cell. 2024;42(8):1319\u201325.","journal-title":"Cancer Cell"},{"issue":"8","key":"8765_CR29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"issue":"8010","key":"8765_CR30","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, Huang Y-K, et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024;629(8010):201\u201310.","journal-title":"Nature"},{"issue":"6","key":"8765_CR31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492\u20139.","journal-title":"Nat Immunol"},{"issue":"8","key":"8765_CR32","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1038\/s44319-024-00191-w","volume":"25","author":"J Russell","year":"2024","unstructured":"Russell J, Chen L, Liu A, Wang J, Ghosh S, Zhong X, et al. Lrp10 suppresses IL7R limiting CD8 T cell homeostatic expansion and anti-tumor immunity. EMBO Rep. 2024;25(8):3601\u201326.","journal-title":"EMBO Rep"},{"issue":"1","key":"8765_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","volume":"23","author":"X Xia","year":"2024","unstructured":"Xia X, Yang Z, Lu Q, Liu Z, Wang L, Du J, et al. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer. 2024;23(1):175.","journal-title":"Mol Cancer"},{"issue":"16","key":"8765_CR34","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1182\/blood-2009-08-237586","volume":"115","author":"A Saunders","year":"2010","unstructured":"Saunders A, Webb LMC, Janas ML, Hutchings A, Pascall J, Carter C, et al. Putative GTPase GIMAP1 is critical for the development of mature B and T lymphocytes. Blood. 2010;115(16):3249\u201357.","journal-title":"Blood"},{"issue":"21","key":"8765_CR35","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309\u201337.","journal-title":"Cell"},{"issue":"1","key":"8765_CR36","doi-asserted-by":"publisher","first-page":"101370","DOI":"10.1016\/j.beem.2019.101370","volume":"34","author":"G Elia","year":"2019","unstructured":"Elia G, Ferrari SM, Galdiero MR, Ragusa F, Paparo SR, Ruffilli I, et al. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Pract Res Clin Endocrinol Metab. 2019;34(1):101370.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"8765_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563\u201380.","journal-title":"Nat Rev Clin Oncol"},{"key":"8765_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","volume":"122","author":"JM Michot","year":"2019","unstructured":"Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M, et al. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer. 2019;122:72\u201390.","journal-title":"Eur J Cancer"},{"issue":"5","key":"8765_CR39","first-page":"525","volume":"47","author":"X Wang","year":"2018","unstructured":"Wang X, Ouyang X, Sun X. [Application of mesenchymal stem cells in antineoplastic drugs delivery for tumor-targeted therapy]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2018;47(5):525\u201333.","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"issue":"11","key":"8765_CR40","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41571-022-00682-6","volume":"19","author":"ER Zanella","year":"2022","unstructured":"Zanella ER, Grassi E, Trusolino L. Towards precision oncology with patient-derived xenografts. Nat Rev Clin Oncol. 2022;19(11):719\u201332.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08765-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08765-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08765-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:48:26Z","timestamp":1789483706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08765-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8765"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08765-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study complied with all applicable ethical standards. The overall study protocol, which explicitly included the procurement and use of PBMCs from healthy volunteers for CAR-T cell generation, was formally reviewed and approved by the Ethics Committee of The First Dongguan Affiliated Hospital of Guangdong Medical University (Approval No. SLYJ202504007).Written informed consent was obtained from all donors prior to collection, in accordance with the Declaration of Helsinki. All animal experiments were approved by the Animal Ethics Committee of Guangdong Medical University (Approval No. GDMU-2024-000023) and conducted in compliance with national animal welfare guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No individual participant data are included in this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1187"}}